iBio, Inc. (IBIO)

NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
2.150
+0.040 (1.90%)
At close: Jul 19, 2024, 4:00 PM
2.130
-0.020 (-0.93%)
After-hours: Jul 20, 2024, 12:57 PM EDT
1.90%
Market Cap 18.54M
Revenue (ttm) 50,000
Net Income (ttm) -23.16M
Shares Out 8.62M
EPS (ttm) -4.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,235
Open 2.100
Previous Close 2.110
Day's Range 2.020 - 2.280
52-Week Range 1.020 - 16.000
Beta -3.36
Analysts Strong Buy
Price Target 5.00 (+132.56%)
Earnings Date May 13, 2024

About IBIO

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers;... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Martin B. Brenner D.V.M., Ph.D.
Employees 26
Stock Exchange NYSEAMERICAN
Ticker Symbol IBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for IBIO stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target
$5.0
(132.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

iBio Closes Sale of Manufacturing Facility in Texas

–  The sale of the facility eliminates $13.2M of secured debt – –  Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, ...

6 weeks ago - GlobeNewsWire

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial r...

2 months ago - GlobeNewsWire

iBio stock nearly tripled on Wednesday: here's why

Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.

4 months ago - Invezz

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –

4 months ago - GlobeNewsWire

iBio Announces $15.0 Million Private Placement

– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven i...

4 months ago - GlobeNewsWire

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

– Deal includes $1 million upfront and potential future milestone payments – – iBio's proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, T...

5 months ago - GlobeNewsWire

iBio Announces Participation in 23rd Annual PepTalk Conference

- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - - VP of Platform Technologies, Matt Gr...

6 months ago - GlobeNewsWire

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Other symbols: ALVRGRIVYNE
6 months ago - Benzinga

iBio Amends and Extends Maturity of Credit Agreement

– Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (N...

7 months ago - GlobeNewsWire

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000...

8 months ago - GlobeNewsWire

iBio Announces Reverse Stock Split

BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the ...

8 months ago - GlobeNewsWire

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -

9 months ago - GlobeNewsWire

iBio Explains Recent Filing of Registration Statement

– No new securities are being registered under the Post-Effective Amendment – – No new securities are being registered under the Post-Effective Amendment –

10 months ago - GlobeNewsWire

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the fili...

10 months ago - GlobeNewsWire

iBio Announces Amendment to Credit Agreement with Woodforest

– Extends maturity date to December 31, 2023 – – Allows time to close pending sale of CDMO facility – BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or ...

10 months ago - GlobeNewsWire

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets –

1 year ago - GlobeNewsWire

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...

1 year ago - GlobeNewsWire

iBio Forges Research Collaboration with the National Institutes of Health

– NIH to evaluate iBio's patented AI-driven epitope steering platform for Lassa fever vaccine development –

1 year ago - GlobeNewsWire

iBio to Participate in the JMP Securities Life Sciences Conference

BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its I...

1 year ago - GlobeNewsWire

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given to...

1 year ago - GlobeNewsWire

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

– Immuno-oncology candidate discovered using iBio's AI epitope steering platform –

1 year ago - GlobeNewsWire

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

- Company has directed antibodies against a specific region of MUC16 -

1 year ago - GlobeNewsWire

iBio Announces Closing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its pre...

1 year ago - GlobeNewsWire

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its pre...

1 year ago - GlobeNewsWire

iBio Announces Proposed Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer an...

1 year ago - GlobeNewsWire